“it is Important to understand when we are more or less time to cover the needs of the country. I hope for 9-12 months,” he told the TASS news Agency. The first drug will get 10-15 regions of the country. However, it is not known what. According to Gunzburg, technology for the production of the Russian vaccine is similar to the production of monoclonal antibodies. He noted that enterprises which continue to produce monoclonal antibodies are already adapted to the production of vaccine. In the next month and a half on each of these areas will be produced every month about a million doses of vaccine. “And by the end of the year, maybe half to two million”, – said the head of the center Gamalei.
the world’s First vaccine against coronavirus, was in Russia on Tuesday, called “Satellite V”. The drug has developed a national research centre of epidemiology and Microbiology named Gamalei, Russian Ministry of health.
According to the Minister of health of Michael Murashko, the first batch of vaccine against COVID-19 will release within two weeks.The production of vaccine is focused primarily on the domestic market.
the Vaccinations will be voluntary. Children and the elderly, at first, to inculcate not be.
in November, the production of its own vaccine COVID-19 is going to run the CPS. As told to “Rossiyskaya Gazeta” in the Department, the vaccine called “Apiversion” developed in Novosibirsk scientific center “Vector”. She could become the second officially registered in Russia immune drug from coronavirus.
a Vaccine Vector already vaccinated 14 volunteers. They all feel good. It would be watched by five days. If all goes well, they will re-vaccinated. Will also begin the first vaccination volunteers in the second phase of the clinical trial. In the second phase, placebo-controlled, will be vaccinated two groups of volunteers – a total of 86 people. The first group will be immunized twice vaccine “Apiversion” with an interval of 21 days. The second group will receive placebo (dummy).
“Apiversion” created based on chemically synthesized peptide antigens of virus proteins in SARS-CoV-2, and other components. It does not contain live attenuated viruses and the genetic material of the coronavirus. Viral vectors, getting into the cage, provide a synthesis of the protective antigen protein S of coronaviruses (SARS-CoV-2). In response to the appearance in the body of foreign protein is the formation of the full antibody and cellular immunity.
